Chin, L. & Gray, J. W.
Translating insights from the cancer genome into clinical practice. Nature
452, 553–563 (2008).
van't Veer, L. J. & Bernards, R.
Enabling personalized cancer medicine through analysis of gene-expression patterns. Nature
452, 564–570 (2008).
Hartwell, L., Mankoff, D., Paulovich, A., Ramsey, S. & Swisher, E.
Cancer biomarkers: a systems approach. Nature Biotechnol.
24, 905–908 (2006).
HUPO initiatives relevant to clinical proteomics. Mol. Cell. Proteomics
3, 298–301 (2004).
Uhlen, M. & Ponten, F.
Antibody-based proteomics for human tissue profiling. Mol. Cell. Proteomics
4, 384–393 (2005).
et al. Distinguishing protein-coding and noncoding genes in the human genome. Proc. Natl Acad. Sci. USA
104, 19428–19433 (2007).
Ponten, F., Jirstrom, K. & Uhlen, M.
The Human Protein Atlas - a tool for pathology. J. Pathol.
216, 387–393 (2008).
Taussig, M. J.
et al. ProteomeBinders: planning a European resource of affinity reagents for analysis of the human proteome. Nature Methods
4, 13–17 (2007).
et al. A human protein atlas for normal and cancer tissues based on antibody proteomics. Mol. Cell. Proteomics
4, 1920–1932 (2005). This paper describes the Human Protein Atlas as an antibody-based proteomics initiative.
Warford, A., Flack, G., Conquer, J. S., Zola, H. & McCafferty, J.
Assessing the potential of immunohistochemistry for systematic gene expression profiling. J. Immunol. Methods
318, 125–137 (2007).
et al. Nuclear expression of the RNA-binding protein RBM3 is associated with an improved clinical outcome in breast cancer. Mod. Pathol.
22, 1564–1574 (2009).
et al. Antibody validation. Biotechniques
48, 197–209 (2010).
et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nature Med.
4, 844–847 (1998). This seminal paper describes TMA technology.
The multitumor (sausage) tissue block: novel method for immunohistochemical antibody testing. Lab. Invest.
55, 244–248 (1986).
Wan, W. H., Fortuna, M. B. & Furmanski, P.
A rapid and efficient method for testing immunohistochemical reactivity of monoclonal antibodies against multiple tissue samples simultaneously. J. Immunol. Methods
103, 121–129 (1987).
Camp, R. L., Neumeister, V. & Rimm, D. L.
A decade of tissue microarrays: progress in the discovery and validation of cancer biomarkers. J. Clin. Oncol.
26, 5630–5637 (2008).
Brennan, D. J.
et al. Contribution of DNA and tissue microarray technology to the identification and validation of biomarkers and personalised medicine in breast cancer. Cancer Genom. Proteom.
4, 3–16 (2007).
Hewitt, S. M.
The application of tissue microarrays in the validation of microarray results. Meth.Enzymol.
410, 400–415 (2006).
Fernandez, D. C., Bhargava, R., Hewitt, S. M. & Levin, I. W.
Infrared spectroscopic imaging for histopathologic recognition. Nature Biotech.
23, 469–474 (2005).
What brown cannot do for you. Nature Biotech.
24, 914–916 (2006).
Rhodes, A., Jasani, B., Barnes, D. M., Bobrow, L. G. & Miller, K. D.
Reliability of immunohistochemical demonstration of oestrogen receptors in routine practice: interlaboratory variance in the sensitivity of detection and evaluation of scoring systems. J. Clin. Pathol.
53, 125–130 (2000).
Brennan, D. J.
et al. Altered cytoplasmic-nuclear ratio of survivin is a prognostic indicator in breast cancer. Clin. Cancer Res.
14, 2681–2689 (2008).
Mulrane, L., Rexhepaj, E., Penney, S., Callanan, J. J. & Gallagher, W. M.
Automated image analysis in histopathology: a valuable tool in medical diagnostics. Expert Rev. Mol. Diagn.
8, 707–725 (2008).
et al. Novel image analysis approach for quantifying expression of nuclear proteins assessed by immunohistochemistry: application to measurement of estrogen and progesterone receptor levels in breast cancer. Breast Cancer Res.
10, R89 (2008).
Rojo, M. G., Garcia, G. B., Mateos, C. P., Garcia, J. G. & Vicente, M. C.
Critical comparison of 31 commercially available digital slide systems in pathology. Int. J. Surg. Pathol.
14, 285–305 (2006).
et al. A high-throughput strategy for protein profiling in cell microarrays using automated image analysis. Proteomics
7, 2142–2150 (2007).
Brennan, D. J.
et al. The transcription factor Sox11 is a prognostic factor for improved recurrence-free survival in epithelial ovarian cancer. Eur. J. Cancer
45, 1510–1517 (2009).
et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N. Engl. J. Med.
353, 2654–2666 (2005).
et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science.
313, 1960–1964 (2006).
Brennan, D. J.
et al. Tumour-specific HMG-CoAR is an independent predictor of recurrence free survival in epithelial ovarian cancer. BMC Cancer
10, 125 (2010).
Camp, R., Chung, G. & Rimm, D.
Automated subcellular localization and quantification of protein expression in tissue microarrays. Nature Med.
8, 1323–1327 (2002).
et al. Classification of breast cancer using genetic algorithms and tissue microarrays. Clin. Cancer Res.
12, 6459–6468 (2006).
et al. Quantitative measurement of epidermal growth factor receptor is a negative predictive factor for tamoxifen response in hormone receptor positive premenopausal breast cancer. J. Clin. Oncol.
25, 3007–3014 (2007).
McCabe, A., Dolled-Filhart, M., Camp, R. L. & Rimm, D. L.
Automated quantitative analysis (AQUA) of in situ protein expression, antibody concentration, and prognosis. J. Natl Cancer Inst.
97, 1808–1815 (2005). This paper reported the demonstration of automated analysis of immunofluorescence.
Camp, R. L., Dolled-Filhart, M., King, B. L. & Rimm, D. L.
Quantitative analysis of breast cancer tissue microarrays shows that both high and normal levels of HER2 expression are associated with poor outcome. Cancer Res.
63, 1445–1448 (2003).
Gould Rothberg, B. E.
et al. Melanoma prognostic model using tissue microarrays and genetic algorithms. J. Clin. Oncol.
27, 5772–5780 (2009).
Hu, S., Loo, J. A. & Wong, D. T.
Human body fluid proteome analysis. Proteomics
6, 6326–6353 (2006).
Anderson, N. L.
et al. The human plasma proteome: a nonredundant list developed by combination of four separate sources. Mol. Cell. Proteomics
3, 311–326 (2004).
Disease proteomics. Nature.
422, 226–232 (2003).
Borrebaeck, C. A. & Wingren, C.
High-throughput proteomics using antibody microarrays: an update. Expert Rev. Mol. Diagn.
7, 673–686 (2007).
Kingsmore, S. F.
Multiplexed protein measurement: technologies and applications of protein and antibody arrays. Nature Rev. Drug Discov.
5, 310–320 (2006).
Wingren, C. & Borrebaeck, C. A.
Antibody microarray analysis of directly labelled complex proteomes. Curr. Opin. Biotechnol.
19, 55–61 (2008).
Chen, S. & Haab, B. B.
Analysis of glycans on serum proteins using antibody microarrays. Methods Mol. Biol.
520, 39–58 (2009).
et al. A strategy for discovery of cancer glyco-biomarkers in serum using newly developed technologies for glycoproteomics. FEBS J.
277, 95–105 (2010).
Schwenk, J. M., Gry, M., Rimini, R., Uhlen, M. & Nilsson, P.
Antibody suspension bead arrays within serum proteomics. J. Proteome Res.
7, 3168–3179 (2008).
Gowan, S. M.
et al. Application of meso scale technology for the measurement of phosphoproteins in human tumor xenografts. Assay Drug Dev. Technol.
5, 391–401 (2007).
Leng, S. X.
et al. ELISA and multiplex technologies for cytokine measurement in inflammation and aging research. J. Gerontol. A Biol. Sci. Med. Sci.
63, 879–884 (2008).
et al. Cytometric bead array: a multiplexed assay platform with applications in various areas of biology. Clin. Immunol.
110, 252–266 (2004).
Elshal, M. F. & McCoy, J. P.
Multiplex bead array assays: performance evaluation and comparison of sensitivity to ELISA. Methods
38, 317–323 (2006).
Khan, S. S., Smith, M. S., Reda, D., Suffredini, A. F. & McCoy, J. P. Jr.
Multiplex bead array assays for detection of soluble cytokines: comparisons of sensitivity and quantitative values among kits from multiple manufacturers. Cytometry B Clin. Cytom.
61, 35–39 (2004).
et al. Validation and comparative analysis of a multiplexed assay for the simultaneous quantitative measurement of Th1/Th2 cytokines in human serum and human peripheral blood mononuclear cell culture supernatants. J. Immunol. Methods
291, 27–38 (2004).
Spurrier, B., Ramalingam, S. & Nishizuka, S.
Reverse-phase protein lysate microarrays for cell signaling analysis. Nature Protoc.
3, 1796–1808 (2008). This paper describes the basis of how RPPAs can be used for pathway diagnostics.
Berg, D., Hipp, S., Malinowsky, K., Bollner, C. & Becker, K. F.
Molecular profiling of signalling pathways in formalin-fixed and paraffin-embedded cancer tissues. Eur. J. Cancer
46, 47–55 (2010).
et al. A portrait of tissue phosphoprotein stability in the clinical tissue procurement process. Mol. Cell. Proteomics
7, 1998–2018 (2008).
Chung, J. L., Lee, S. J., Kris, Y., Braunschweig, T. & Hewitt, S. M.
A well-based reverse-phase protein array applicable to extracts from formalin-fixed paraffin-embedded tissue. Proteomics Clin. Appl.
2, 1539–1547 (2008).
et al. Zeptosens' protein microarrays: a novel high performance microarray platform for low abundance protein analysis. Proteomics
2, 383–393 (2002).
et al. A highly sensitive near-infrared fluorescent detection method to analyze signalling pathways by reverse-phase protein array. Proteomics
9, 5446–5454 (2009).
Brennan, D. J.
et al. Application of DNA microarray technology in determining breast cancer prognosis and therapeutic response. Expert Opin. Biol. Ther.
5, 1069–1083 (2005).
Brennan, D. J. & Gallagher, W. M.
Prognostic ability of a panel of immunohistochemistry markers - retailoring of an 'old solution'. Breast Cancer Res.
10, 102 (2008).
van 't Veer, L. J.
et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature
415, 530–536 (2002). This seminal paper describes the 70 gene prognostic signature for breast cancer that is now the basis of the MammaPrint assay.
Glas, A. M.
et al. Converting a breast cancer microarray signature into a high-throughput diagnostic test. BMC Genomics
7, 278 (2006).
et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N. Engl. J. Med.
351, 2817–2826 (2004). This paper describes the Oncotype Dx assay.
TAILORx: trial assigning individualized options for treatment (Rx). Clin. Breast Cancer
7, 347–350 (2006).
et al. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J. Natl Cancer Inst.
98, 1183–1192 (2006).
Tan, E. H.
et al. A multicentre phase II gene expression profiling study of putative relationships between tumour biomarkers and clinical response with erlotinib in non-small-cell lung cancer. Ann. Oncol.
21, 217–222 (2010).
Chen, H. Y.
et al. A five-gene signature and clinical outcome in non-small-cell lung cancer. N. Engl. J. Med.
356, 11–20 (2007).
Guo, N. L.
et al. Confirmation of gene expression-based prediction of survival in non-small cell lung cancer. Clin. Cancer Res.
14, 8213–8220 (2008).
Hao, J. M.
et al. A five-gene signature as a potential predictor of metastasis and survival in colorectal cancer. J. Pathol.
220, 475–489 (2010).
Garman, K. S.
et al. A genomic approach to colon cancer risk stratification yields biologic insights into therapeutic opportunities. Proc. Natl Acad. Sci. USA.
105, 19432–19437 (2008).
et al. Stage II colon cancer prognosis prediction by tumor gene expression profiling. J. Clin. Oncol.
24, 4685–4691 (2006).
Cheville, J. C.
et al. Gene panel model predictive of outcome in men at high-risk of systemic progression and death from prostate cancer after radical retropubic prostatectomy. J. Clin. Oncol.
26, 3930–3936 (2008).
et al. Identification of prognostic biomarkers for prostate cancer. Clin. Cancer Res.
14, 1734–1743 (2008).
Alizadeh, A. A.
et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature
403, 503–511 (2000).
et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N. Engl. J. Med.
346, 1937–1947 (2002). This seminal paper describes the classification of B cell lymphoma.
et al. Stromal gene signatures in large-B-cell lymphomas. N. Engl. J. Med.
359, 2313–2323 (2008).
Whiteaker, J. R.
et al. Antibody-based enrichment of peptides on magnetic beads for mass-spectrometry-based quantification of serum biomarkers. Anal. Biochem.
362, 44–54 (2007).
Anderson, N. L.
et al. Mass spectrometric quantitation of peptides and proteins using Stable Isotope Standards and Capture by Anti-Peptide Antibodies (SISCAPA). J. Proteome Res.
3, 235–244 (2004).
et al. Detection of pancreatic cancer using antibody microarray-based serum protein profiling. Proteomics
8, 2211–2219 (2008).
et al. Antibody microarray profiling reveals individual and combined serum proteins associated with pancreatic cancer. Cancer Res.
65, 11193–11202 (2005).
et al. Serum proteome profiling of metastatic breast cancer using recombinant antibody microarrays. Eur. J. Cancer.
44, 472–480 (2008).
et al. Dual-color proteomic profiling of complex samples with a microarray of 810 cancer-related antibodies. Mol. Cell. Proteomics
9, 1271–1280 (2010).
et al. A multi-marker assay to distinguish malignant melanomas from benign nevi. Proc. Natl Acad. Sci. USA
106, 6268–6272 (2009). This paper describes an IHC assay for the diagnosis of malignant melanoma.
Ring, B. Z.
et al. A novel five-antibody immunohistochemical test for subclassification of lung carcinoma. Mod. Pathol.
22, 1032–1043 (2009).
Lynch, T. J.
et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med.
350, 2129–2139 (2004).
Paez, J. G.
et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science.
304, 1497–1500 (2004).
et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin. Cancer Res.
10, 5367–5374 (2004).
et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA
295, 2492–2502 (2006).
et al. Concordance among gene-expression-based predictors for breast cancer. N. Engl. J. Med.
355, 560–569 (2006).
et al. Novel prognostic immunohistochemical biomarker panel for estrogen receptor-positive breast cancer. J. Clin. Oncol.
24, 3039–3047 (2006). This paper describes a five marker IHC prognostic assay for breast cancer, which is an example of integrating transcriptomic and proteomic data.
Ross, D. T.
et al. Chemosensitivity and stratification by a five monoclonal antibody immunohistochemistry test in the NSABP B14 and B20 trials. Clin. Cancer Res.
14, 6602–6609 (2008).
Crabb, S. J.
et al. Can clinically relevant prognostic subsets of breast cancer patients with four or more involved axillary lymph nodes be identified through immunohistochemical biomarkers: a tissue microarray feasibility study. Breast Cancer Res.
10, R6 (2008).
et al. A signature predictive of disease outcome in breast carcinomas, identified by quantitative immunocytochemical assays. Int. J. Cancer
124, 2124–2134 (2009).
Kim, H. L.
et al. Using protein expressions to predict survival in clear cell renal carcinoma. Clin. Cancer Res.
10, 5464–5471 (2004).
et al. Molecular signatures of localized clear cell renal cell carcinoma to predict disease-free survival after nephrectomy. Cancer Epidemiol. Biomarkers Prev.
18, 894–900 (2009).
Kobunai, T., Watanabe, T., Yamamoto, Y. & Eshima, K.
The frequency of KRAS mutation detection in human colon carcinoma is influenced by the sensitivity of assay methodology: a comparison between direct sequencing and real-time PCR. Biochem. Biophys. Res. Commun.
395, 158–162 (2010).
Banck, M. S. & Grothey, A.
Biomarkers of resistance to epidermal growth factor receptor monoclonal antibodies in patients with metastatic colorectal cancer. Clin. Cancer Res.
15, 7492–7501 (2009).
Siena, S., Sartore-Bianchi, A., Di Nicolantonio, F., Balfour, J. & Bardelli, A.
Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. J. Natl Cancer Inst.
101, 1308–1324 (2009).
Weinstein, I. B.
Cancer. Addiction to oncogenes - the Achilles heal of cancer. Science
297, 63–64 (2002).
Sawyers, C. L.
Shifting paradigms: the seeds of oncogene addiction. Nature Med.
15, 1158–1161 (2009).
Thomas, G. V.
et al. Antibody-based profiling of the phosphoinositide 3-kinase pathway in clinical prostate cancer. Clin. Cancer Res.
10, 8351–8356 (2004).
et al. Mutations of the BRAF gene in human cancer. Nature
417, 949–954 (2002). This is a key paper outlining why the identification of the correct patient cohort for molecular therapeutics is of utmost importance.
Wan, P. T.
et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell
116, 855–867 (2004).
Amaravadi, R. K.
et al. Phase II trial of temozolomide and sorafenib in advanced melanoma patients with or without brain metastases. Clin. Cancer Res.
15, 7711–7718 (2009).
et al. Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J. Clin. Oncol.
27, 2823–2830 (2009).
McDermott, D. F.
et al. Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group. J. Clin. Oncol.
26, 2178–2185 (2008).
Flaherty, K. T.
et al. Phase I study of PLX4032: proof of concept for V600E BRAF mutation as a therapeutic target in human cancer. J. Clin. Oncol. Abstr.
27, 9000 (2009).
et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature
464, 431–435 (2010).
et al. Prognostic significance of activated AKT expression in soft-tissue sarcoma. Clin. Cancer Res.
12, 3070–3077 (2006).
et al. Dysregulated PI3K/Akt/PTEN pathway is a marker of a short disease-free survival in node-negative breast carcinoma. Hum. Pathol.
40, 1408–1417 (2009).
et al. Correlation between clinical outcome and growth factor pathway expression in osteogenic sarcoma. Cancer.
115, 5243–5250 (2009).
et al. Overexpression of phospho-eIF4E is associated with survival through AKT pathway in non-small cell lung cancer. Clin. Cancer Res.
16, 240–248 (2010). This paper describes an example of IHC-based pathway analysis.
et al. Gene and protein expression markers of response to combined antiangiogenic and epidermal growth factor targeted therapy in renal cell carcinoma. Ann. Oncol.
20 Jan 2010 (doi:10.1093/annonc/mdp600).
et al. Antibody-based proteomics for esophageal cancer: identification of proteins in the nuclear factor-κB pathway and mitotic checkpoint. Cancer science.
100, 1612–1622 (2009).
et al. Mining tissue microarray data to uncover combinations of biomarker expression patterns that improve intermediate staging and grading of clear cell renal cell cancer. Clin. Cancer Res.
16, 88–98 (2010).
Pernas, F. G.
et al. Proteomic signatures of epidermal growth factor receptor and survival signal pathways correspond to gefitinib sensitivity in head and neck cancer. Clin. Cancer Res.
15, 2361–2372 (2009). This paper describes an example of combining RPPAs and IHC to carry out pathway diagnostics and identify predictive biomarkers.
Gutman, S. & Kessler, L.
The US Food and Drug Administration perspective on cancer biomarker development. Nature Rev. Cancer
6, 565–571 (2006).
Sawyers, C. L.
The cancer biomarker problem. Nature
452, 548–552 (2008).
et al. Vascular endothelial growth factor targeted therapy in the perioperative setting: implications for patient care. Lancet Oncol.
11, 373–382 (2010).
Bergers, G. & Hanahan, D.
Modes of resistance to anti-angiogenic therapy. Nature Rev. Cancer
8, 592–603 (2008).
Azam, F., Mehta, S. & Harris, A. L.
Mechanisms of resistance to antiangiogenesis therapy. Eur. J. Cancer
46, 1323–1332 (2010).
Byers, L. A.
et al. Serum signature of hypoxia-regulated factors is associated with progression after induction therapy in head and neck squamous cell cancer. Mol. Cancer Ther.
9, 1755–1763 (2010).
et al. Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. J. Clin. Oncol.
28, 453–459 (2010). This paper describes the utility of multiplex bead assays to predictive markers for anti-angiogenic treatment.
Nikolinakos, P. G.
et al. Plasma cytokine and angiogenic factor profiling identifies markers associated with tumor shrinkage in early-stage non-small cell lung cancer patients treated with pazopanib. Cancer Res.
70, 2171–2179 (2010).
et al. Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. PLoS Med.
5, e232 (2008).
Bossuyt, P. M.
et al. The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration. Ann. Intern. Med.
138, W1–W12 (2003).
et al. A genecentric Human Protein Atlas for expression profiles based on antibodies. Mol. Cell. Proteomics
7, 2019–2027 (2008).
et al. A whole-genome bioinformatics approach to selection of antigens for systematic antibody generation. Proteomics
8, 2832–2839 (2008).
et al. Towards a human proteome atlas: high-throughput generation of mono-specific antibodies for tissue profiling. Proteomics
5, 4327–4337 (2005).
et al. Antibody-based tissue profiling as a tool for clinical proteomics. Clin. Proteomics
1, 285–299 (2004).
Andersson, A. C.
et al. Analysis of protein expression in cell microarrays: a tool for antibody-based proteomics. J. Histochem. Cytochem.
54, 1413–1423 (2006).
et al. Toward a confocal subcellular atlas of the human proteome. Mol. Cell. Proteomics
7, 499–508 (2008).
et al. A web-based tool for in silico biomarker discovery based on tissue-specific protein profiles in normal and cancer tissues. Mol. Cell. Proteomics
7, 825–844 (2008).
et al. Transfer and multiplex immunoblotting of a paraffin embedded tissue. Proteomics
6, 767–774 (2006).
Paweletz, C. P.
et al. Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front. Oncogene
20, 1981–1989 (2001).
Petricoin, E. F., Zoon, K. C., Kohn, E. C., Barrett, J. C. & Liotta, L. A.
Clinical proteomics: translating benchside promise into bedside reality. Nature Rev. Drug Discov.
1, 683–695 (2002).
Haab, B. B., Dunham, M. J. & Brown, P. O.
Protein microarrays for highly parallel detection and quantitation of specific proteins and antibodies in complex solutions. Genome Biol.
2, research0004.1–research0004.13 (2001).
Lizardi, P. M.
et al. Mutation detection and single-molecule counting using isothermal rolling-circle amplification. Nature Genet.
19, 225–232 (1998).
Rockberg, J., Lofblom, J., Hjelm, B., Uhlen, M. & Stahl, S.
Epitope mapping of antibodies using bacterial surface display. Nature Methods
5, 1039–1045 (2008).
van Zonneveld, A. J., van den Berg, B. M., van Meijer, M. & Pannekoek, H.
Identification of functional interaction sites on proteins using bacteriophage-displayed random epitope libraries. Gene
167, 49–52 (1995).
Christmann, A., Wentzel, A., Meyer, C., Meyers, G. & Kolmar, H.
Epitope mapping and affinity purification of monospecific antibodies by Escherichia coli cell surface display of gene-derived random peptide libraries. J. Immunol. Methods
257, 163–173 (2001).
Petersen, G., Song, D., Hugle-Dorr, B., Oldenburg, I. & Bautz, E. K.
Mapping of linear epitopes recognized by monoclonal antibodies with gene-fragment phage display libraries. Mol. Gen. Genet.
249, 425–431 (1995).
Stadler, C., Skogs, M., Brismar, H., Uhlen, M. & Lundberg, E.
A single fixation protocol for proteome-wide immunofluorescence localization studies. J. Proteomics
73, 1067–1078 (2010).
et al. The impact of tissue fixatives on morphology and antibody-based protein profiling in tissues and cells. J. Histochem. Cytochem.
58, 237–246 (2010).